Services
Therapeutic Development
Creating targeted treatments designed to improve patient outcomes and quality of life Protocol TNBC_003 Antibody Drug Conjugate Development (Monoclonal Antibody, cleaved linkage with drug payload) for TNBC, utilizing the EGFR (Epidermal Growth Factor Receptor) and VEGF (Vascoendothelial Growth Factor Pathways)
Clinical Trials
Oncogenexe Biotech’s Clinical Trials service supports the design and execution of oncology-focused studies to evaluate safety, efficacy, and patient outcomes. Protocol_ TNBC_0_001 A multicentre double-blind placebo-based Phase II Interventional trial evaluating the efficacy of Antibody Drug Conjugate BL-B01D1 in association with Gefitinib, an EGFR tyrosine kinase inhibitor (TKI), in participants stricken with Locally/Advanced Metastatic Basal Like Triple Negative Breast Cancer (TNBC), across sites in Southern Africa and Sub-Saharan Africa Protocol_ PDAC_0_001 A multicentre double blind placebo Phase II interventional study evaluating the phosphoinositide 3 kinase (PI3K) pathway in participants stricken Ductal Adenocarcinoma with locally or advanced Pancreatic Cancer, and the noted targeted therapies,Tesalisib in combination with Samotolisib across participants in South Africa Protocol_DIH_0_001 A Multicentre Open Labelled Phase 1 Observational Trial evaluating the genomic alterations (most notably Epidermal Growth Factor Receptor, EGFR) associated within Non-Small Cell lung Cancer, Breast Cancer and Pancreatic Cancer-stricken Participants (Formalin Fixed Paraffin Embedded Solid tumour biopsies), evaluating the TMB (tumour mutational burden) and MSI (microsatellite instability) across participants in Southern Africa
Patient Support
Providing comprehensive care and resources to patients during their treatment journey.
Mentorship Programmes - Medical and Scientific Life Science Fields
Specifically designed for aspiring molecular biology affiliated medical scientists and doctors (in the genetics, microbiology and biochemistry fields)